Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIBOCICLIB vs RIFAXIMIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIBOCICLIB vs RIFAXIMIN: Safety Overview

Metric RIBOCICLIB RIFAXIMIN
Total FAERS Reports 27,997 13,861
Deaths Reported 4,501 5,009
Death Rate 16.1% 36.1%
Hospitalizations 6,700 4,847
Average Patient Age 60.2 yrs 63.2 yrs
% Female Patients 99.0% 54.9%
FDA Approval Date Mar 13, 2017 Mar 24, 2010
Manufacturer Novartis Pharmaceuticals Corporation Salix Pharmaceuticals, Inc.
Route ORAL ORAL
Marketing Status Prescription Prescription